Loading stock data…
MBRX
$2.41-0.06 (-2.43%)
After Hours$2.38-0.03 (-1.21%)· Last close Jun 9
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Moleculin Biotech, Inc. in the Healthcare sector is trading at $2.41 with a market capitalization of $13M. Wall Street consensus targets $21.00 (3 analysts), implying a +771.4% move over the next 12 months. The stock is currently near its 52-week low of $1.79, remaining 60.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +771.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.41
Potential Downside
0%
Whystock Fair Value$2.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$21.00+771.4%
Range$10.00 – $31.00
Fundamentals
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-199.78%
Volume
Today's trading volume
169,360
Recent News
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
Moleculin Biotech Inc. (NASDAQ:MBRX) said it remains on track to unblind the first set of data from its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML), before June 30, 2026. • Moleculin Biotech shares are retreating from recent levels. What’s behind MBRX decline? The MIRACLE study is comparing two dosing arms of Annamycin plus cytarabine against a control arm using cytarabine with placebo in patients wh
Moleculin Biotech announces issuance of Canadian patent covering Annamycin
Moleculin Biotech (MBRX) announced that the Canadian Intellectual Property Office, CIPO, has issued a notice of allowance for Patent Application No. 3,142,510 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from the application is expected to be issued in the coming months. When issued, the patent claims will cover methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term currently extending until June 2040, su
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Several Insiders Invested In Moleculin Biotech Flagging Positive News
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Moleculin Biotech prices 16.08M shares at 37c in public offering
Moleculin Biotech (MBRX) announced the pricing of a public offering consisting of 16,080,000 shares of common stock and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock and accompanying Series E warrants of 37c. The Series E warrants will have an exercise price of 37c per share, are exercisable upon stockholder approval, and will expire five years following the initial exercise date. The offering is expected